PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för linagliptin. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

74 hits

Bibliografisk träff 2012-10-01

Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.

Barnett AH, Patel S, Harper R, Toorawa R, Thiemann S, von Eynatten M, Woerle HJ.

Diabetes Obes Metab · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1111/dom.12011

Bibliografisk träff 2012-10-01

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study.

McGill JB, Sloan L, Newman J, Patel S, Sauce C, von Eynatten M, Woerle HJ.

Diabetes Care · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.2337/dc12-0706

Bibliografisk träff 2012-09-18

Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus.

Rauch T, Graefe-Mody U, Deacon CF, Ring A, Ring A, Holst JJ, Woerle HJ, Dugi KA, Heise T.

Diabetes Ther · research-article; journal article · DOI 10.1007/s13300-012-0010-y

Bibliografisk träff 2012-09-01

Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice.

Chen L, Klein T, Leung PS.

Curr Mol Med · research support, non-u.s. gov't; journal article · DOI 10.2174/156652412802480970

Bibliografisk träff 2012-09-01

Linagliptin: a review of its use in the management of type 2 diabetes mellitus.

Deeks ED.

Drugs · review; journal article · DOI 10.2165/11209570-000000000-00000

Bibliografisk träff 2012-08-29

Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.

Lewin AJ, Arvay L, Liu D, Patel S, von Eynatten M, Woerle HJ.

Clin Ther · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.clinthera.2012.07.008

Bibliografisk träff 2012-08-28

Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride?

Christensen M, Knop FK.

Nat Rev Endocrinol · news · DOI 10.1038/nrendo.2012.163

Bibliografisk träff 2012-08-13

Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial.

Ross SA, Rafeiro E, Meinicke T, Toorawa R, Weber-Born S, Woerle HJ.

Curr Med Res Opin · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1185/03007995.2012.714360

Bibliografisk träff 2012-07-03

The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice.

Jelsing J, Vrang N, van Witteloostuijn SB, Mark M, Klein T.

J Endocrinol · research support, non-u.s. gov't; journal article · DOI 10.1530/joe-11-0479

Bibliografisk träff 2012-07-01

Pharmacokinetics of linagliptin in subjects with hepatic impairment.

Graefe-Mody U, Rose P, Retlich S, Ring A, Ring A, Waldhauser L, Cinca R, Woerle HJ.

Br J Clin Pharmacol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/j.1365-2125.2012.04173.x

Bibliografisk träff 2012-07-01

Clinical pharmacokinetics and pharmacodynamics of linagliptin.

Graefe-Mody U, Retlich S, Friedrich C.

Clin Pharmacokinet · research support, non-u.s. gov't; review; journal article · DOI 10.2165/11630900-000000000-00000

Bibliografisk träff 2012-06-28

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.

Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, Dugi KA, Woerle HJ.

Lancet · comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s0140-6736(12)60691-6

Bibliografisk träff 2012-06-25

Evaluation of body fat composition after linagliptin treatment in a rat model of diet-induced obesity: a magnetic resonance spectroscopy study in comparison with sibutramine.

Klein T, Niessen HG, Ittrich C, Mayoux E, Mueller HP, Cheetham S, Stiller D, Kassubek J, Mark M.

Diabetes Obes Metab · letter; comparative study; research support, non-u.s. gov't · DOI 10.1111/j.1463-1326.2012.01629.x

Bibliografisk träff 2012-06-22

Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity.

Kern M, Klöting N, Niessen HG, Thomas L, Stiller D, Mark M, Klein T, Blüher M.

PLoS One · research-article; journal article · DOI 10.1371/journal.pone.0038744

Bibliografisk träff 2012-06-12

Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension.

Gomis R, Owens DR, Taskinen MR, Del Prato S, Patel S, Pivovarova A, Schlosser A, Woerle HJ.

Int J Clin Pract · journal article · DOI 10.1111/j.1742-1241.2012.02975.x

Bibliografisk träff 2012-06-01

Linagliptin: a novel methylxanthin based approved dipeptidyl peptidase-4 inhibitor.

Agrawal R, Jain P, Dikshit SN.

Curr Drug Targets · review; journal article · DOI 10.2174/138945012800675731

Bibliografisk träff 2012-05-16

Combination therapy in type 2 diabetes mellitus: adding linagliptin to a stable regimen of metformin and a sulfonylurea.

Aronson R.

Expert Opin Pharmacother · comment; journal article · DOI 10.1517/14656566.2012.689825

Bibliografisk träff 2012-05-01

The concentration-dependent binding of linagliptin (BI 1356) and its implication on efficacy and safety.

Wright S, Singh RP, Retlich S, Graefe-Mody U, Derendorf H.

Int J Clin Pharmacol Ther · research support, non-u.s. gov't; journal article · DOI 10.5414/cp201630

Bibliografisk träff 2012-04-04

The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice.

Schürmann C, Linke A, Engelmann-Pilger K, Steinmetz C, Mark M, Pfeilschifter J, Klein T, Frank S.

J Pharmacol Exp Ther · research support, non-u.s. gov't; journal article · DOI 10.1124/jpet.111.191098

Bibliografisk träff 2012-04-01

[Pharmacological and clinical profiles of the DPP-4 inhibitor linagliptin (Trazenta)].

Ohmura T, Hayashi N, Encinas J.

Nihon Yakurigaku Zasshi · review; journal article · DOI 10.1254/fpj.139.174

Bibliografisk träff 2012-03-21

Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study.

Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ.

Diabetes Obes Metab · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1111/j.1463-1326.2012.01590.x

Bibliografisk träff 2012-03-21

Review of linagliptin for the treatment of type 2 diabetes mellitus.

Neumiller JJ, Setter SM.

Clin Ther · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.clinthera.2012.02.029

Bibliografisk träff 2012-03-20

The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Singh-Franco D, McLaughlin-Middlekauff J, Elrod S, Harrington C.

Diabetes Obes Metab · meta-analysis; systematic review; journal article · DOI 10.1111/j.1463-1326.2012.01586.x

Bibliografisk träff 2012-02-16

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.

Schernthaner G, Barnett AH, Emser A, Patel S, Troost J, Woerle HJ, von Eynatten M.

Diabetes Obes Metab · research support, non-u.s. gov't; journal article · DOI 10.1111/j.1463-1326.2012.01565.x

Bibliografisk träff 2012-02-07

Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus.

Neumiller JJ.

Ann Pharmacother · research support, non-u.s. gov't; review; journal article · DOI 10.1345/aph.1q522

Bibliografisk träff 2012-02-01

[Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination].

Scheen AJ, Van Gaal LF.

Rev Med Liege · journal article; english abstract

Bibliografisk träff 2012-01-17

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.

Kawamori R, Inagaki N, Araki E, Watada H, Hayashi N, Horie Y, Sarashina A, Gong Y, von Eynatten M, Woerle HJ, Dugi KA.

Diabetes Obes Metab · clinical trial, phase iii; clinical trial, phase ii; comparative study; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/j.1463-1326.2011.01545.x

Bibliografisk träff 2012-01-11

Linagliptin-a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapy.

Gallwitz B.

Clin Med Insights Endocrinol Diabetes · review-article; journal article · DOI 10.4137/cmed.s7274

Bibliografisk träff 2012-01-10

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.

Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ.

Cardiovasc Diabetol · meta-analysis; research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1475-2840-11-3

Bibliografisk träff 2012-01-02

The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats.

Hocher B, Sharkovska Y, Mark M, Klein T, Pfab T.

Int J Cardiol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ijcard.2011.12.007